We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
We’re right, we believe, in assuming that as a pharmaceutical compliance professional, you like everything in hard numbers. Facts, clarification, proof, justification for a decision: Everything looks better with a sound, supporting statistic attached, doesn’t it? Or does it? As experts in pharma analytics, we also realize that the sheer volume of this data can be overwhelming. The more sophisticated your compliance workflow, the more intimidating approaching a single workbook can be. Almost every compliance officer we have spoken to has agreed. In a high-pressure environment, (like the one dominating your floor before the CMS submission deadline), a stacked spend workbook promises more than just more work (read late nights). Just thinking about the heightened: · Probability for error · […]
At qordata, we are blessed and grateful in that our oldest customers are still with us. It’s a privilege we never take for granted. In fact, sometimes we go the other way and ask ourselves if we’d do the same if we were in their place. We are happy to say the answer is always a YES. And of course, as analysts, it’s inevitable that our decisions steer clear of snap judgments and are backed by sound, quantified, rationale. Save Time: Ever notice how your life’s best decisions demanded the most out of you the first time round? And nothing seemed as challenging ever after? Deciding on the right college, the right employer, the right car, the right house? (Even […]
Violating the General Data Protection Regulation (GDPR) will be a form of self-punishment for medical drug and device companies, especially those headquartered in the EU. We’re not just considering the substantial monetary penalties involved. There’s also the reputational risk, litigation and poor goodwill to consider, all of which will affect such organizations for the long-term, and impede their competitiveness in an industry which is already very competitive. Despite the clear implications of not being GDPR compliant, not all companies will be ready with a program on 25th May 2018. According to a survey qordata conducted during the Life Sciences GDPR Bootcamp, none of the compliance/transparency professionals indicated complete readiness, though 7.14% stated readiness at 90%; of the respondents, 14.29% said […]